Join
Live feed
·
PRReleasevia Quantisnow
Kura Oncology Inc. logo

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

ByQuantisnow·Wall Street's wire, on your screen.
KURA· Kura Oncology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KURA (Kura Oncology Inc.) and more on Quantisnow.